NEW YORK – August 8, 2019 – The Cardiovascular Research Foundation (CRF) has announced the 12 late-breaking trials and 16 late-breaking science presentations that will be reported at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place September 25 – 29, 2019 at The Moscone Center in San Francisco, California.
Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that will impact patient care and how physicians treat heart disease, the leading cause of death in the world. The studies selected examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that demonstrate potential to treat or prevent cardiovascular disease.
Late-breaking trials and science will be presented in the Main Arena and highlighted during press conferences scheduled for Thursday, September 26; Friday, September 27; Saturday, September 28; and Sunday, September 29.
The complete agenda for TCT 2019 is available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty. Media are invited to attend TCT and can apply for media credentials online at: https://www.crf.org/tct/press/for-the-media/press-resources.
Thursday, September 26, 2019
Late-Breaking Trials
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing PCI
Roxana Mehran
Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT
Stephan Windecker
IDEAL-LM: A Randomized Trial of a Bioabsorbable Polymer DES With 4-Month DAPT vs a Durable Polymer DES With 12-Month DAPT in Patients With Left Main Coronary Artery Disease
Robert-Jan Van Geuns
Late-Breaking Science
EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated a Bioabsorbable Polymer-Based Everolimus-Eluting Stent
Ajay J. Kirtane
MODEL U-SES: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated A Bioabsorbable Polymer-Based Sirolimus-Eluting Stent
Ken Kozuma
AUGUSTUS ACS: A 2 × 2 Factorial Randomized Trial of Apixaban vs Warfarin and Aspirin vs Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome
Stephan Windecker
TWILIGHT: Thrombogenicity Substudy: Impact of Ticagrelor Alone vs Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI
Usman Baber
Friday, September 27, 2019
Late-Breaking Trials
SCOPE I: A Randomized Trial of the ACURATE Neo vs the SAPIEN 3 Bioprosthesis in Patients With Severe Aortic Stenosis
Jonas Lanz
PORTICO: A Randomized Trial of Portico vs Commercially Available Transcatheter Aortic Valves in Patients With Severe Aortic Stenosis
Gregory P. Fontana
PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves
Raj Makkar
Late-Breaking Science
Mitral Valve-in-Valve: One-Year Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprotheses
Mayra Guerrero
STS/ACC TVT Registry: MitraClip Operator Volume-Outcome Relationship in the United States
Adnan K. Chhatriwalla
STS Registry: Mitral Valve Surgery Institutional Volume-Outcome Relationship in the United States
Vinay Badhwar
A Propensity Score-Matched Analysis of Transcatheter Tricuspid Valve Treatment vs Medical Treatment in Patients With Severe Tricuspid Regurgitation
Maurizio Taramasso
Saturday, September 28, 2019
Late-Breaking Trials
COAPT: Three-Year Outcomes From a Randomized Trial of the MitraClip in Patients With Heart Failure and Severe Secondary Mitral Regurgitation
Michael J. Mack
PARTNER 2A: Five-Year Outcomes From a Randomized Trial of Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis
Vinod H. Thourani
EXCEL: Five-Year Outcomes From a Randomized Trial of PCI vs CABG in Patients With Left Main Coronary Artery Disease
Gregg W. Stone
Late-Breaking Science
COMPLETE Timing Substudy: A Randomized Trial of Complete Staged Revascularization vs Infarct Artery PCI Alone in Patients With Acute Myocardial Infarction and Multivessel Disease – Importance of Revascularization Timing
David A. Wood
EURO-CTO: Three-Year Outcomes From a Randomized Trial of PCI vs Medical Therapy in Patients With Chronic Total Coronary Occlusions
Gerald S. Werner
MODERATO II: A Double-Blind Randomized Trial of Cardiac Neuromodulation Therapy in Patients With Hypertension
Karl-Heinz Kuck
LEVANT: Five-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease
Kenneth Ouriel
Friday, September 29, 2019
Late-Breaking Trials
COAPT: Cost-Effectiveness Analysis From a Randomized Trial of the MitraClip in Patients With Heart Failure and Severe Secondary Mitral Regurgitation
Suzanne J. Baron
PARTNER 3: Health Status Outcomes From a Randomized Trial of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low Surgical Risk
Suzanne J. Baron
REMEDIAL III: A Randomized Trial of Urine Flow Rate-Guided vs LVEDP-Guided Hydration in Patients at High Risk for Contrast Nephropathy
Carlo Briguori
Late-Breaking Science
BIODEGRADE: A Large-Scale Randomized Trial of a Thin-Strut Bioabsorbable Polymer-Based DES vs a Thick-Strut Bioabsorbable Polymer-Based DES in an All-Comers Population With Coronary Artery Disease
IN-HO CHAE
BLADE-PCI: A Randomized Trial of Liposomal Alendronate in Patients With Diabetes Undergoing PCI
Philippe Genereux
FORZA: A Randomized Trial of Fractional Flow Reserve vs Optical Coherence Tomography to Guide Revascularization of Intermediate Coronary Stenoses
Francesco Burzotta
IVUS-XPL: Five-Year Outcomes From a Randomized Trial of Intravascular Ultrasound-Guided vs Angiography-Guided PCI of Long Coronary Lesions
Myeong-Ki Hong
Receive updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 31st year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field. TCT also includes interactive training pavilions where clinicians can gain vital skills to apply immediately to their practices.
For more information, visit www.crf.org and www.tctconference.com.
###
